Ye, Fei

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 2,674

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 2,156

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 642

Early-Onset Atrial Fibrillation and the Prevalence of Rare Variants in Cardiomyopathy and Arrhythmia Genes

Yoneda, Z. T., Anderson, K. C., Quintana, J. A., O’Neill, M. J., Sims, R. A., Glazer, A. M., Shaffer, C. M., Crawford, D. M., Stricker, T., Ye, F., et al. (2021) · JAMA Cardiology

Cardiac electrophysiology and arrhythmiasAtrial Fibrillation Management and Outcomes

Cited by 192

SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer

Ichihara, E., Westover, D., Meador, C. B., Yan, Y., Bauer, J. A., Lu, P., Ye, F., Kulick, A., de Stanchina, E., McEwen, R., et al. (2017) · Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 150

Association of Anti–Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma

Quach, H. T., Dewan, A. K., Davis, E. J., Ancell, K. K., Fan, R., Ye, F., & Johnson, D. B. (2019) · JAMA Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 107

Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center

Johnson, D. B., Friedman, D. L., Berry, E., Decker, I., Ye, F., Zhao, S., Morgans, A. K., Puzanov, I., Sosman, J. A., & Lovly, C. M. (2015) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 101

Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 Therapy

Shah, K. P., Song, H., Ye, F., Moslehi, J. J., Balko, J. M., Salem, J.-E., & Johnson, D. B. (2020) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 64

Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand

Patrinely, J. R., Young, A. C., Quach, H., Williams, G. R., Ye, F., Fan, R., Horn, L., Beckermann, K. E., Gillaspie, E. A., Sosman, J. A., et al. (2020) · European Journal of Cancer

Cancer Immunotherapy and BiomarkersCancer survivorship and care

Cited by 61

Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic

Samuels, J. M., Ye, F., Irlmeier, R., Silver, H., Srivastava, G., & Spann, M. (2025) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 35